Posted by Michael Wonder on 08 Sep 2021
FDA grants Madorra breakthrough device designation status for treatment of moderate to severe vulvovaginal atrophy
8 September 2021 - Clinical trials of Madorra therapy system show promising results for treatment of vulvovaginal atrophy.
The FDA has granted Madorra breakthrough device designation for the company’s non-invasive, home-use device for a subset of women experiencing moderate to severe vulvovaginal atrophy, a component of genitourinary syndrome of menopause.
